GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00439544 | Colorectum | CRC | cellular component maintenance | 15/2078 | 61/18723 | 2.26e-03 | 2.18e-02 | 15 |
GO:00007235 | Colorectum | CRC | telomere maintenance | 26/2078 | 131/18723 | 2.29e-03 | 2.20e-02 | 26 |
GO:00068692 | Colorectum | CRC | lipid transport | 63/2078 | 398/18723 | 2.36e-03 | 2.26e-02 | 63 |
GO:00060664 | Colorectum | CRC | alcohol metabolic process | 57/2078 | 353/18723 | 2.37e-03 | 2.27e-02 | 57 |
GO:00716924 | Colorectum | CRC | protein localization to extracellular region | 59/2078 | 368/18723 | 2.37e-03 | 2.27e-02 | 59 |
GO:00519612 | Colorectum | CRC | negative regulation of nervous system development | 28/2078 | 145/18723 | 2.43e-03 | 2.30e-02 | 28 |
GO:00099521 | Colorectum | CRC | anterior/posterior pattern specification | 36/2078 | 201/18723 | 2.56e-03 | 2.40e-02 | 36 |
GO:00704824 | Colorectum | CRC | response to oxygen levels | 56/2078 | 347/18723 | 2.60e-03 | 2.40e-02 | 56 |
GO:00482554 | Colorectum | CRC | mRNA stabilization | 14/2078 | 56/18723 | 2.65e-03 | 2.42e-02 | 14 |
GO:00015034 | Colorectum | CRC | ossification | 64/2078 | 408/18723 | 2.73e-03 | 2.49e-02 | 64 |
GO:00507682 | Colorectum | CRC | negative regulation of neurogenesis | 27/2078 | 140/18723 | 2.92e-03 | 2.64e-02 | 27 |
GO:00070044 | Colorectum | CRC | telomere maintenance via telomerase | 16/2078 | 69/18723 | 3.12e-03 | 2.75e-02 | 16 |
GO:0060537 | Colorectum | CRC | muscle tissue development | 63/2078 | 403/18723 | 3.17e-03 | 2.78e-02 | 63 |
GO:0032355 | Colorectum | CRC | response to estradiol | 27/2078 | 141/18723 | 3.24e-03 | 2.81e-02 | 27 |
GO:00516474 | Colorectum | CRC | nucleus localization | 8/2078 | 24/18723 | 3.25e-03 | 2.81e-02 | 8 |
GO:19039005 | Colorectum | CRC | regulation of viral life cycle | 28/2078 | 148/18723 | 3.29e-03 | 2.83e-02 | 28 |
GO:00097495 | Colorectum | CRC | response to glucose | 37/2078 | 212/18723 | 3.54e-03 | 3.00e-02 | 37 |
GO:00713224 | Colorectum | CRC | cellular response to carbohydrate stimulus | 30/2078 | 163/18723 | 3.69e-03 | 3.12e-02 | 30 |
GO:00714534 | Colorectum | CRC | cellular response to oxygen levels | 32/2078 | 177/18723 | 3.69e-03 | 3.12e-02 | 32 |
GO:00442423 | Colorectum | CRC | cellular lipid catabolic process | 37/2078 | 214/18723 | 4.16e-03 | 3.40e-02 | 37 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0002014 | Esophagus | ESCC | Citrate cycle (TCA cycle) | 27/4205 | 30/8465 | 3.48e-06 | 1.94e-05 | 9.95e-06 | 27 |
hsa0120023 | Esophagus | ESCC | Carbon metabolism | 79/4205 | 115/8465 | 2.50e-05 | 1.21e-04 | 6.22e-05 | 79 |
hsa0123023 | Esophagus | ESCC | Biosynthesis of amino acids | 49/4205 | 75/8465 | 4.35e-03 | 1.12e-02 | 5.74e-03 | 49 |
hsa0062023 | Esophagus | ESCC | Pyruvate metabolism | 32/4205 | 47/8465 | 8.11e-03 | 1.94e-02 | 9.94e-03 | 32 |
hsa0002015 | Esophagus | ESCC | Citrate cycle (TCA cycle) | 27/4205 | 30/8465 | 3.48e-06 | 1.94e-05 | 9.95e-06 | 27 |
hsa0120033 | Esophagus | ESCC | Carbon metabolism | 79/4205 | 115/8465 | 2.50e-05 | 1.21e-04 | 6.22e-05 | 79 |
hsa0123033 | Esophagus | ESCC | Biosynthesis of amino acids | 49/4205 | 75/8465 | 4.35e-03 | 1.12e-02 | 5.74e-03 | 49 |
hsa0062033 | Esophagus | ESCC | Pyruvate metabolism | 32/4205 | 47/8465 | 8.11e-03 | 1.94e-02 | 9.94e-03 | 32 |
hsa0120010 | Liver | NAFLD | Carbon metabolism | 26/1043 | 115/8465 | 1.39e-03 | 1.71e-02 | 1.38e-02 | 26 |
hsa0120011 | Liver | NAFLD | Carbon metabolism | 26/1043 | 115/8465 | 1.39e-03 | 1.71e-02 | 1.38e-02 | 26 |
hsa0120021 | Liver | Cirrhotic | Carbon metabolism | 64/2530 | 115/8465 | 6.37e-09 | 1.18e-07 | 7.26e-08 | 64 |
hsa006208 | Liver | Cirrhotic | Pyruvate metabolism | 29/2530 | 47/8465 | 5.90e-06 | 5.95e-05 | 3.67e-05 | 29 |
hsa0002010 | Liver | Cirrhotic | Citrate cycle (TCA cycle) | 21/2530 | 30/8465 | 6.56e-06 | 6.24e-05 | 3.84e-05 | 21 |
hsa012304 | Liver | Cirrhotic | Biosynthesis of amino acids | 35/2530 | 75/8465 | 1.54e-03 | 7.83e-03 | 4.83e-03 | 35 |
hsa0120031 | Liver | Cirrhotic | Carbon metabolism | 64/2530 | 115/8465 | 6.37e-09 | 1.18e-07 | 7.26e-08 | 64 |
hsa0062011 | Liver | Cirrhotic | Pyruvate metabolism | 29/2530 | 47/8465 | 5.90e-06 | 5.95e-05 | 3.67e-05 | 29 |
hsa0002011 | Liver | Cirrhotic | Citrate cycle (TCA cycle) | 21/2530 | 30/8465 | 6.56e-06 | 6.24e-05 | 3.84e-05 | 21 |
hsa0123011 | Liver | Cirrhotic | Biosynthesis of amino acids | 35/2530 | 75/8465 | 1.54e-03 | 7.83e-03 | 4.83e-03 | 35 |
hsa0120041 | Liver | HCC | Carbon metabolism | 89/4020 | 115/8465 | 3.92e-11 | 6.56e-10 | 3.65e-10 | 89 |
hsa0002021 | Liver | HCC | Citrate cycle (TCA cycle) | 28/4020 | 30/8465 | 1.08e-07 | 1.44e-06 | 8.02e-07 | 28 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
PC | SNV | Missense_Mutation | novel | c.1378N>A | p.Ala460Thr | p.A460T | P11498 | protein_coding | deleterious(0.01) | benign(0.108) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PC | SNV | Missense_Mutation | novel | c.1726N>G | p.Ser576Ala | p.S576A | P11498 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AR-A256-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | PD |
PC | SNV | Missense_Mutation | | c.619N>C | p.Val207Leu | p.V207L | P11498 | protein_coding | deleterious(0.01) | possibly_damaging(0.822) | TCGA-B6-A0I6-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
PC | SNV | Missense_Mutation | | c.584C>T | p.Ala195Val | p.A195V | P11498 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-B6-A0IB-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | PD |
PC | SNV | Missense_Mutation | rs119103242 | c.1748N>A | p.Arg583His | p.R583H | P11498 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-BH-A18G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PC | SNV | Missense_Mutation | | c.1217G>A | p.Arg406His | p.R406H | P11498 | protein_coding | deleterious(0) | probably_damaging(0.985) | TCGA-C8-A138-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
PC | SNV | Missense_Mutation | | c.730N>T | p.His244Tyr | p.H244Y | P11498 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-D8-A1XQ-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PC | SNV | Missense_Mutation | | c.1848N>A | p.Met616Ile | p.M616I | P11498 | protein_coding | deleterious(0.01) | benign(0.059) | TCGA-EW-A1PD-01 | Breast | breast invasive carcinoma | Male | <65 | I/II | Chemotherapy | docetaxel | SD |
PC | SNV | Missense_Mutation | novel | c.151N>A | p.Arg51Ser | p.R51S | P11498 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-EW-A6SC-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | aromatase | SD |
PC | SNV | Missense_Mutation | | c.2395N>A | p.Asp799Asn | p.D799N | P11498 | protein_coding | tolerated(0.18) | probably_damaging(0.967) | TCGA-DS-A0VK-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | carboplatin | PD |